Chromoblastomycosis in Southern Madagascar: Our Experience
Marco Sanlorenzo1*, Marina Cornacchiari1, Fabio Crema2
1ODV H&T*, Italy.
2San Luigi Gonzaga Hospital, Orbassano (TO), Italy.
*Corresponding Author: Marco Sanlorenzo, Via Tellini 22, 10034 Chivasso TO, Italy.
DOI: https://doi.org/10.58624/SVOAMR.2026.04.007
Received: February 10, 2026
Published: March 03, 2026
Citation: Sanlorenzo M, Cornacchiari M, Crema F. Chromoblastomycosis in Southern Madagascar: Our Experience. SVOA Medical Research 2026, 4:2, 39-51. doi: 10.58624/SVOAMR.2026.04.007
Abstract
The authors present their experience in the detection, clinical diagnosis, treatment and outcomes of 20 subjects affected by chromoblastomycosis identified in two regions of Southern Madagascar over a long period (1990–2025). Mucocutaneous manifestations proved difficult to resolve therapeutically, not only in relation to the drugs used and the duration of treatment, but also because of patient compliance and the numerous logistical problems present in these regions. The proportion of clinically cured subjects was 30%, and this included only those with mild to moderate forms. The most frequently used drug was terbinafine.
Keywords: Chromoblastomycosis; Neglected tropical diseases; Subcutaneous mycoses; Antifungal therapy; Terbinafine; Madagascar